Tramadol (Ultram) is often prescribed for analgesia because it’s easy to write for (especially at hospital discharge); however, its pharmacology makes it unreliable for pain control. The parent compound has only weak affinity for the mu opioid receptor, so most of the meaningful opioid effect comes from its active metabolite O-desmethyltramadol. That metabolite is produced by CYP2D6, which varies widely among individuals due to both genetic variation and drug interactions. Poor metabolizers generate very little active metabolite and often report that tramadol does nothing. Ultra-rapid metabolizers produce more active metabolite, feel a more substantial opioid effect, and are more likely to experience sedation and respiratory depression from an otherwise modest dose.
Tramadol ends up being a complicated way to get codeine level pain relief with extra baggage. Across studies in acute and chronic pain, its analgesic effect is similar to other weak opioids or opioid acetaminophen combinations, with no real gain in function or long-term outcomes. Reviews in primary care report slight improvements in pain scores, along with common side effects such as nausea, dizziness, and central nervous system symptoms, and little solid data support long-term safety. It does not outperform simple strategies built on acetaminophen, nonsteroidal agents when appropriate, and a predictable short-acting opioid when needed. As a CVICU intensivist, this is typically my multimodal analgesia strategy (coupled with peripheral nerve blocks and muscle relaxants) at baseline.
Tramadol also behaves like an antidepressant by blocking serotonin and norepinephrine reuptake. This stacks on top of SSRIs, SNRIs, tricyclics, and other serotonergic drugs and is a well-described trigger for serotonin toxicity. Patients can return with agitation, tremor, clonus, and autonomic instability after receiving tramadol as a basic analgesic. CYP2D6 poor metabolizers and patients on CYP2D6 inhibitors are especially vulnerable because they accumulate more parent drug with stronger monoaminergic effects, yet still do not get reliable pain control.
Finally, seizures can occur even at therapeutic doses and are more likely with higher doses, overdose, or combinations that increase tramadol exposure through CYP2D6 inhibition. Recent data in older adults show a higher seizure risk with tramadol plus CYP2D6-inhibiting antidepressants than with combinations that use neutral agents, and this pattern is not seen with other opioids. All of this paints a picture of a drug with inconsistent analgesia, metabolism-driven variability, and added risks of serotonin toxicity and seizures.
Here are some PubMed IDs to review the data: 40940161, 39667604, 29752906, 19724727, 41061201
Leave a Reply